Policy & Research

Share

Testimony: A Health Impact Assessment on Legalization of Medical Marijuana in Kansas

By Tatiana Y. Lin, M.A. | March 16, 2017

Testimony: A Health Impact Assessment on Legalization of Medical Marijuana in Kansas

While KHI was presenting testimony on this bill, Representatives John Eplee, Ronald Ellis, Steven Crum and Abraham Rafie reviewed documents provided by KHI to supplement the testimony about the research KHI has conducted on potential health effects of medical marijuana.

View larger photo

On March 15, 2017, Tatiana Y. Lin, M.A., KHI Senior Analyst and Strategy Team Leader, provided neutral testimony on House Bill 2152 to the House Committee on Health and Human Services. The bill would, among other things, authorize hemp treatments for certain medical conditions.

During the testimony, KHI discussed findings and recommendations from its 2015 health impact assessment (HIA) Potential Health Effects of Legalizing Medical Marijuana in Kansas.

For more information, see the following documents:

Testimony: A Health Impact Assessment on Legalization of Medical Marijuana in Kansas
Executive Summary: Potential Health Effects of Legalizing Medical Marijuana in Kansas
Key Findings and Recommendations: Potential Health Effects of Legalizing Medical Marijuana in Kansas
Map: Medical Marijuana Laws in the United States (November 2016)

The Kansas Health Institute delivers credible information and research enabling policy leaders to make informed health policy decisions that enhance their effectiveness as champions for a healthier Kansas. The Kansas Health Institute is a nonprofit, nonpartisan health policy and research organization based in Topeka, established in 1995 with a multiyear grant from the Kansas Health Foundation.